These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34397529)

  • 1. Kidney dysfunction has a major impact on the effect of idarucizumab for dabigatran reversal.
    Athavale A; Jamshidi N; Roberts DM
    Eur J Anaesthesiol; 2021 Sep; 38(9):1005-1006. PubMed ID: 34397529
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre.
    Wheeler M; Borrie A; Dookia R; Carter J
    Intern Med J; 2019 Oct; 49(10):1316-1320. PubMed ID: 31602769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
    Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarucizumab: The Antidote for Reversal of Dabigatran.
    Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
    Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
    Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
    Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarucizumab for Dabigatran Reversal Guideline.
    Reardon DP; Owusu K
    Crit Pathw Cardiol; 2016 Jun; 15(2):33-5. PubMed ID: 27183250
    [No Abstract]   [Full Text] [Related]  

  • 14. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran Reversal with Idarucizumab in an Emergency Lumbar Puncture: A Case Report.
    Spagnolello O; Letteri F; Falcou A; Cipollone L; De Michele M; Bertazzoni G; Toni D
    Curr Drug Saf; 2019; 14(1):40-42. PubMed ID: 30112997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe dabigatran intoxication complicated by insufficient reversal by idarucizumab].
    Hellfritzsch M; Hvas AM
    Ugeskr Laeger; 2020 Apr; 182(15):. PubMed ID: 32286218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of dabigatran with idarucizumab in hyperacute stroke: a new paradigm?
    Ting A; Venkat AR; Gawarikar Y; Patel R
    Med J Aust; 2019 Apr; 210(7):302-303.e1. PubMed ID: 30924530
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.
    Ng FC; Bice J; Rodda A; Lee-Archer M; Crompton DE
    J Neurol; 2017 Mar; 264(3):591-594. PubMed ID: 28168523
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
    Ohya Y; Makihara N; Wakisaka K; Morita T; Ago T; Kitazono T; Takaba H
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):e128-e131. PubMed ID: 29555397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
    Laxamana LC; Co COC; Yu JRT; Mojica CV; Iboleon-Dy MAM; Domingo AMC; Ilano KCS; Macrohon-Valdez MCZ
    Clin Ther; 2020 Sep; 42(9):1840-1845. PubMed ID: 32778345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.